^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Follicular Lymphoma
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Innovent Biologics Press Release
    Title:

    Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

    Published date:
    10/09/2020
    Excerpt:
    Innovent Biologics, Inc....and Eli Lilly and Company...today jointly announce that HALPRYZA® (rituximab injection), a recombinant human/murine chimeric monoclonal antibody drug co-developed by Innovent and Lilly, has been officially approved by the National Medical Products Administration (NMPA) of China for patients with diffuse large b cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL) in China.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    01/20/2021
    Excerpt:
    Follicular Lymphoma: First-line therapy for elderly or infirm…Other recommended regimens...Chlorambucil ± rituximab...Preferred Regimens…Bendamustine + Obinutuzumab or rituximab...Other Recommended Regimens…Cyclophosphamide ± rituximab
    Secondary therapy:
    bendamustine; cyclophosphamide; chlorambucil
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/26/2020
    Excerpt:
    ...rituximab in combination with CHOP or bendamustine should be used if complete remission and long PFS are the therapeutic goals [I, B]…Consensus-driven recommendations- For stage III/IV FL with high tumor burden and >65 years and < 65 years immunoCHT such as R-B (rituximab-bendamustine)...chlorambucil plus rituximab remain alternatives for patients with a low-risk profile or when conventional ChT is contraindicated [III, C]…
    Secondary therapy:
    chlorambucil; bendamustine
    DOI:
    10.1016/j.annonc.2020.11.008
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    11/26/2020
    Excerpt:
    Antibody monotherapy (rituximab, radioimmunotherapy)...remain alternatives for patients with a low-risk profile or when conventional ChT is contraindicated [III, C]….Rituximab maintenance every 2 months for 2 years is recommended after immunochemotherapy [I, B]....In symptomatic cases with low tumour burden, rituximab monotherapy may be applied.
    DOI:
    10.1016/j.annonc.2020.11.008
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Follicular Lymphoma:.First-line therapy…Lenalidomide + rituximab
    Secondary therapy:
    lenalidomide